Evidence map›Paper›PMID 28786987›Full record

Trial reportPloS one2017

Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial.

Kyung Won Park, Eun-Joo Kim, Hyun Jeong Han, Yong S Shim, Jae C Kwon, Bon D Ku, Kee Hyung Park, Hyon-Ah Yi, Kwang K Kim, Dong Won Yang and 12 more

Registry-linked trialAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01380288 (Changes of Cognitive Function in Patients With Mild to Moderate Alzheimer's Disease Associated With or Without White Matter Changes After Rivastigmine Patch Therapy - Multi-center, Prospective, Open-label Clinical Trial), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01380288 nacompletednot on this map

Changes of Cognitive Function in Patients With Mild to Moderate Alzheimer's Disease Associated With or Without White Matter Changes After Rivastigmine Patch Therapy - Multi-center, Prospective, Open-label Clinical Trial

TypeinterventionalSponsorDong-A UniversityRan2011 to 2017Enrolled300ConditionsAlzheimer's DiseaseArmsrivastigmine patch
3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Pathophysiological Role and Medicinal Chemistry of AMolecules (Basel, Switzerland) · 2022
    Review
  6. ACurrent medicinal chemistry · 2022
    Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Kyung Won ParkDepartment of Neurology, Cognitive Disorders and Dementia Center, Dong-A University College of Medicine and Institute of Convergence Bio-Health, Busan, South Korea.ORCID http://orcid.org/0000-0002-4180-8626
Eun-Joo KimDepartment of Neurology, Pusan National University Hospital and Biomedical Research Institute, Pusan National University School of Medicine, Busan, South Korea.
Hyun Jeong HanDepartment of Neurology, Seonam University College of Medicine, Myongji Hospital, Goyang, South Korea.
Yong S ShimDepartment of Neurology, Holy Family Hospital, The Catholic University of Korea, School of Medicine, Bucheon, South Korea.
Jae C KwonDepartment of Neurology, Changwon Fatima Hospital, Changwon, South Korea.
Bon D KuDepartment of Neurology, Catholic Kwandong University College of Medicine, Gangneung, South Korea.
Kee Hyung ParkDepartment of Neurology, Gachon University Gil Hospital, Incheon, South Korea.
Hyon-Ah YiDepartment of Neurology, Keimyung University College of Medicine, Daegu, South Korea.
Kwang K KimDepartment of Neurology, Dongguk University College of Medicine, Seoul, South Korea.
Dong Won YangDepartment of Neurology, The Catholic University of Korea, School of Medicine, Seoul, South Korea.
Ho-Won LeeDepartment of Neurology, Kyungpook National University School of Medicine, Daegu, South Korea.
Heeyoung KangDepartment of Neurology, Gyeongsang National University College of Medicine, Jinju, South Korea.
Oh Dae KwonDepartment of Neurology, Catholic University of Daegu School of Medicine, Daegu, South Korea.
SangYun KimDepartment of Neurology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
Jae-Hyeok LeeDepartment of Neurology, Pusan National University Yangsan Hospital, Yangsan, South Korea.
Eun Joo ChungDepartment of Neurology, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea.
Sang-Won ParkDepartment of Neurology, Daegu Fatima Hospital, Daegu, South Korea.
Mee Young ParkDepartment of Neurology, Yeungnam University College of Medicine, Daegu, South Korea.
Bora YoonDepartment of Neurology, Konyang University College of Medicine, Daejeon, South Korea.
Byeong C KimDepartment of Neurology, Chonnam National University School of Medicine, Gwangju, South Korea.
Sang Won SeoDepartment of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Seong Hye ChoiDepartment of Neurology, Inha University School of Medicine, Incheon, South Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveStudies investigating the impact of white matter hyperintensities (WMHs) on the response of acetylcholinesterase inhibitors in patients with Alzheimer's disease (AD) have presented inconsistent results. We aimed to compare the effects of the rivastigmine patch between patients with AD with minimal WMHs and those with moderate WMHs.

methodsThree hundred patients with mild to moderate AD were enrolled in this multicenter prospective open-label study and divided into two groups. Group 1 comprised patients with AD with minimal WMHs and group 2 comprised those with moderate WMHs. The patients were treated with a rivastigmine patch for 24 weeks. Efficacy measures were obtained at baseline and after 24 weeks. The primary endpoint was the change in the AD Assessment Scale-Cognitive subscale (ADAS-Cog) from the baseline to the end of the study.

resultsOf the 300 patients, there were 206 patients in group 1 and 94 patients in group 2. The intention-to-treat group comprised 198 patients (group 1, n = 136; group 2, n = 46) during the 24-week study period. Demographic factors did not differ between group 1 and group 2. There were no significant differences in change in ADAS-cog between group 1 (-0.62±5.70) and group 2 (-0.23±5.98) after the 24-week rivastigmine patch therapy (p = 0.378). The patients in group 1 had a 0.63-point improvement from baseline on the Frontal Assessment Battery, while group 2 had a 0.16-point decline compared to baseline at the end of the study (p = 0.037). The rates of adverse events (AEs) (42.6 vs. 40.3%) and discontinuation due to AEs (10.3% vs. 4.3%) did not differ between the groups.

conclusionsAlthough the efficacy and tolerability of rivastigmine patch therapy were not associated with WMH severity in patients with AD, some improvement in frontal function was observed in those with minimal WMHs.

trial registrationClinicalTrials.gov NCT01380288.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseBrainCholinesterase InhibitorsFemaleHumansMaleMiddle AgedNeuroprotective AgentsRepublic of KoreaRivastigmineSeverity of Illness IndexTransdermal PatchTreatment OutcomeWhite MatterCholinesterase InhibitorsNeuroprotective AgentsRivastigmine

Identifiers

PMID28786987
PMCPMC5546604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.